ABSTRACT
BACKGROUND: Simvastatin administration to decompensated cirrhosis patients improved Child-Pugh (CP) at the end of a safety trial (EST). AIM: To evaluate whether simvastatin reduces cirrhosis severity through a secondary analysis of the safety trial. METHODS: Thirty patients CP class (CPc) CPc A (n = 6), CPc B (n = 22), and CPc C (n = 2) received simvastatin for one year. PRIMARY ENDPOINT: cirrhosis severity. Secondary endpoints: health-related quality of life (HRQoL) and hospitalizations for cirrhosis complications. RESULTS: Cirrhosis severity decreased baseline versus EST only across CP score (7.3 ± 1.3 versus 6.7 ± 1.7, P = 0.041), and CPc: 12 patients lessened from CPc B to CPc A, and three patients increased from CPc A to CPc B (P = 0.029). Due to cirrhosis severity changes and differences in clinical outcomes, 15 patients completed the trial as CPc AEST and another 15 as CPc B/C. At baseline, CPc AEST showed greater albumin and high-density lipoprotein cholesterol concentrations than CPc B/C (P = 0.036 and P = 0.028, respectively). Comparing EST versus baseline, only in CPc AEST, there was a reduction in white-cell blood (P = 0.012), neutrophils (P = 0.029), monocytes (P = 0.035), and C-reactive protein (P = 0.046); an increase in albumin (P = 0.011); and a recovery in HRQoL (P < 0.030). Finally, admissions for cirrhosis complications decreased in CPc AEST versus CPc B/C (P = 0.017). CONCLUSIONS: Simvastatin would reduce cirrhosis severity only in CPc B at baseline in a suitable protein and lipid milieu, possibly due to its anti-inflammatory effects. Furthermore, only in CPc AEST would improve HRQoL and reduce admissions by cirrhosis complications. However, as these outcomes were not primary endpoints, they require validation.
Subject(s)
Quality of Life , Simvastatin , Humans , Albumins , Inflammation/drug therapy , Liver Cirrhosis/complications , Liver Cirrhosis/diagnosis , Liver Cirrhosis/drug therapy , Simvastatin/therapeutic useABSTRACT
This review summarizes the safety and efficacy of statins in patients with cirrhosis. Due to concerns about the safety of statins in patients with impaired liver function, they have recently been investigated as a potential treatment option in cirrhosis. The most clinically significant adverse event is statin-related myopathy, and this may be related to the high serum statin concentrations in the setting of severely impaired liver function. Rhabdomyolysis is the most serious and potentially life-threatening manifestation. It has recently been demonstrated that the recommended dose of simvastatin in patients with decompensated cirrhosis would be 20 mg/d because higher values, such as 40 mg/d, are associated with many adverse events, especially muscle injury. Likewise, simvastatin should not be administered to patients with Model for End-stage Liver Disease score > 12 and/or Child-Pugh class C because of the high risk of severe muscle injury. Due to the pleiotropic effects, the focus on statins has shifted from being considered harmful to something useful. Through these effects, statins could prevent liver-related morbidity and mortality in cirrhotic patients. Observational studies in large populations of patients with cirrhosis have shown that treatment with statins to decrease high cholesterol levels was associated with a reduced risk of hepatic decompensation, hepatocellular carcinoma development and death. The few randomized controlled trials in patients with cirrhosis and portal hypertension showed that statins lower portal pressure, quite likely through a reduction in hepatic resistance. Another large randomized controlled trial in patients with variceal bleeding showed that simvastatin in addition to standard of care did not prevent rebleeding but improved survival rate. Despite these encouraging outcomes, the quality of the evidence regarding the use of statins is low or very low due to the observational characteristics of most of the studies involved. Therefore, it is advisable to perform further randomized controlled trials on a large series of patients with hard clinical endpoints, using different statin types and varying doses. The objectives would be to prevent liver-related morbidity and mortality rather than treating cirrhosis complications to take additional information that makes it possible to add statins to the standard of care of these patients.
Subject(s)
End Stage Liver Disease , Esophageal and Gastric Varices , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Hypertension, Portal , Liver Neoplasms , Gastrointestinal Hemorrhage , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Liver Cirrhosis/complications , Liver Cirrhosis/drug therapy , Severity of Illness IndexABSTRACT
BACKGROUND & AIMS: It is not clear how often patients who are on gluten-free diets (GFDs) for treatment of celiac disease still are exposed to gluten. We studied levels of gluten immunogenic peptides (GIP) in fecal and urine samples, collected over 4 weeks, from patients with celiac disease on a long-term GFD. METHODS: We performed a prospective study of 53 adults with celiac disease who had been on a GFD for more than 2 years (median duration, 8 y; interquartile range, 5-12 y) in Argentina. At baseline, symptoms were assessed by the celiac symptom index questionnaire. Patients collected stool each Friday and Saturday and urine samples each Sunday for 4 weeks. We used a commercial enzyme-linked immunosorbent assay to measure GIP in stool and point-of-care tests to measure GIP in urine samples. RESULTS: Overall, 159 of 420 stool and urine samples (37.9%) were positive for GIP; 88.7% of patients had at least 1 fecal or urine sample that was positive for GIP (median, 3 excretions). On weekends (urine samples), 69.8% of patients excreted GIP at least once, compared with 62.3% during weekdays (stool). The number of patients with a sample that was positive for GIP increased over the 4-week study period (urine samples in week 1 vs week 4: P < .05). Patients with symptoms had more weeks in which GIP was detected in stool than patients without symptoms (P < .05). The number of samples that were positive for GIP correlated with titers of deamidated gliadin peptide IgA in patients' blood samples, but not with levels of tissue transglutaminase. CONCLUSIONS: Patients with celiac disease on a long-term GFD still frequently are exposed to gluten. Assays to detect GIP in stool and urine might be used to assist dietitians in assessment of GFD compliance.
Subject(s)
Celiac Disease , Gliadin , Adult , Diet, Gluten-Free , Glutens , Humans , Peptides , Prospective StudiesABSTRACT
BACKGROUND: The high mortality rate of decompensated cirrhosis underlines the need for new treatments. Experimental models of cirrhosis and its reported relationship with atherosclerotic cardiovascular disease have provided data supporting the rational use of statins in these patients. However, little is known about the safety of statins in this setting. AIM: We evaluate the safety of chronic simvastatin treatment in patients with decompensated cirrhosis. METHODS: We conducted a prospective, open, uncontrolled, phase 2a trial in 30 patients with Child-Pugh class A (n = 6), B (n = 22), and C (n = 2) decompensated cirrhosis. The patients received standard treatment throughout the trial plus simvastatin 20 mg/day for 2 weeks and thereafter simvastatin 40 mg/day up to 1 year. RESULTS: Sixteen out of 30 patients (53.3%) showed adverse events, including gastrointestinal toxicity (36.7%), muscle injury (MI) (36.7%), and headache (13.3%). No liver injury was registered. Due to MI alone, simvastatin dosage was reduced in 23.4% of cases and transiently interrupted in 13.3%. Once these adverse events were overcome, simvastatin was resumed until the end of the trial. MI was associated with baseline MELD score > 12 (p = 0.035) and with baseline Child-Pugh class C. No MI was associated with final Child-Pugh score ≤ 6 (p = 0.030) or final Child-Pugh class A (p = 0.020). CONCLUSIONS: Chronic treatment with simvastatin 40 mg/day in patients with decompensated cirrhosis was associated with several adverse events, being MI the only clinically significant one, which appears to be related to the simvastatin dosage and the degree of cirrhosis severity. Noticeably, no liver injury was recorded.
Subject(s)
Drug-Related Side Effects and Adverse Reactions , Liver Cirrhosis , Liver/drug effects , Simvastatin , Argentina/epidemiology , Cardiovascular Diseases/prevention & control , Disease Progression , Dose-Response Relationship, Drug , Drug-Related Side Effects and Adverse Reactions/diagnosis , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/etiology , Female , Gastrointestinal Diseases/chemically induced , Gastrointestinal Diseases/diagnosis , Gastrointestinal Diseases/epidemiology , Headache/chemically induced , Headache/diagnosis , Headache/epidemiology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Liver Cirrhosis/diagnosis , Liver Cirrhosis/epidemiology , Male , Middle Aged , Myalgia/chemically induced , Myalgia/diagnosis , Myalgia/epidemiology , Outcome and Process Assessment, Health Care , Risk Assessment/methods , Risk Assessment/statistics & numerical data , Severity of Illness Index , Simvastatin/administration & dosage , Simvastatin/adverse effectsABSTRACT
Resumen En los primeros años del siglo XX, no existía en México un hospital que tuviera la capacidad de atender los problemas de salud de la niñez mexicana, lo que hacía necesaria la construcción de una institución moderna para atenderlos. En 1933, esta situación llevó a un grupo de médicos, encabezados por el Dr. Federico Gómez Santos, a solicitar y conseguir que el presidente de la República, Abelardo L. Rodríguez, reconociera la imperiosa necesidad de contar con un hospital de niños y aprobara el proyecto para su construcción. Luego de diez años de lucha en el campo político, social y económico, y con el apoyo de los presidentes Lázaro Cárdenas y Manuel Ávila Camacho, el 30 de abril de 1943 se inauguró el Hospital Infantil de México. Hoy, después de 75 años de su creación, el hospital ha resistido la prueba del tiempo y mantiene incólume sus principios de asistencia, enseñanza e investigación, emergiendo como la cuna de la pediatría mexicana y latinoamericana.
Abstract In the early years of the 20th century, no hospital in Mexico held the capacity to address the health problems of Mexican children, making it necessary to build a modern institution to take care of these issues. This situation mobilized a group of doctors led by Dr. Federico Gómez Santos to seek the acknowledgement of the President, Abelardo L. Rodríguez, of the urgent need of a children's hospital. Later, the President approved the project for its construction in 1933. After 10 years of struggle in the political, social and economic fields, and with the support of presidents Lázaro Cárdenas and Manuel Ávila Camacho, the Hospital Infantil de México was inaugurated on April 30th, 1943. Today, 75 years after its creation, the hospital has withstood the test of time maintaining intact its principles of assistance, teaching and research, and emerging as the cradle of Mexican and Latin American pediatrics.
Subject(s)
Child , History, 20th Century , History, 21st Century , Humans , Hospitals, Pediatric/history , MexicoABSTRACT
In the early years of the 20th century, no hospital in Mexico held the capacity to address the health problems of Mexican children, making it necessary to build a modern institution to take care of these issues. This situation mobilized a group of doctors led by Dr. Federico Gómez Santos to seek the acknowledgement of the President, Abelardo L. Rodríguez, of the urgent need of a children's hospital. Later, the President approved the project for its construction in 1933. After 10 years of struggle in the political, social and economic fields, and with the support of presidents Lázaro Cárdenas and Manuel Ávila Camacho, the Hospital Infantil de México was inaugurated on April 30th, 1943. Today, 75 years after its creation, the hospital has withstood the test of time maintaining intact its principles of assistance, teaching and research, and emerging as the cradle of Mexican and Latin American pediatrics.
En los primeros años del siglo XX, no existía en México un hospital que tuviera la capacidad de atender los problemas de salud de la niñez mexicana, lo que hacía necesaria la construcción de una institución moderna para atenderlos. En 1933, esta situación llevó a un grupo de médicos, encabezados por el Dr. Federico Gómez Santos, a solicitar y conseguir que el presidente de la República, Abelardo L. Rodríguez, reconociera la imperiosa necesidad de contar con un hospital de niños y aprobara el proyecto para su construcción. Luego de diez años de lucha en el campo político, social y económico, y con el apoyo de los presidentes Lázaro Cárdenas y Manuel Ávila Camacho, el 30 de abril de 1943 se inauguró el Hospital Infantil de México. Hoy, después de 75 años de su creación, el hospital ha resistido la prueba del tiempo y mantiene incólume sus principios de asistencia, enseñanza e investigación, emergiendo como la cuna de la pediatría mexicana y latinoamericana.
Subject(s)
Hospitals, Pediatric/history , Child , History, 20th Century , History, 21st Century , Humans , MexicoABSTRACT
BACKGROUND: Life-long removal of gluten from the diet is currently the only way to manage celiac disease (CeD). Until now, no objective test has proven useful to objectively detect ingested gluten in clinical practice. Recently, tests that determine consumption of gluten by assessing excretion of gluten immunogenic peptides (GIP) in stool and urine have been developed. Their utility, in comparison with conventional dietary and analytical follow-up strategies, has not been fully established. AIM: To assess the performance of enzyme-linked immunosorbent assay (ELISA) and point-of-care tests (PoCTs) for GIP excretion in CeD patients on gluten-free diet (GFD). METHODS: We conducted an observational, prospective, cross-sectional study in patients following a GFD for at least two years. Using the Gastrointestinal Symptom Rating Scale questionnaire, patients were classified at enrollment as asymptomatic or symptomatic. Gluten consumption was assessed twice by 3-d dietary recall and GIP excretion (by ELISA in stool and PoCTs (commercial kits for stool and urine) in two consecutive samples. These samples and dietary reports were obtained 10 day apart one from the other. Patients were encouraged to follow their usual GFD during the study period. RESULTS: Forty-four patients were enrolled, of which 19 (43.2%) were symptomatic despite being on a GFD. Overall, 83 sets of stool and/or urine samples were collected. Eleven out of 44 patients (25.0%) had at least one positive GIP test. The occurrence of at least one positive test was 32% in asymptomatic patients compared with 15.8% in symptomatic patients. GIP was concordant with dietary reports in 65.9% of cases (Cohen´s kappa: 0.317). PoCT detected dietary indiscretions. Both ELISA and PoCT in stool were concordant (concomitantly positive or negative) in 67 out of 74 (90.5%) samples. Excretion of GIP was detected in 7 (8.4%) stool and/or urine samples from patients considered to be strictly compliant with the GFD by dietary reports. CONCLUSION: GIP detects dietary transgressions in patients on long-term GFD, irrespective of the presence of symptoms. PoCT for GIP detection constitutes a simple home-based method for self-assessment of dietary indiscretions.
Subject(s)
Celiac Disease/diet therapy , Diet, Gluten-Free , Glutens/analysis , Patient Compliance , Peptides/analysis , Adult , Aged , Aged, 80 and over , Asymptomatic Diseases , Celiac Disease/diagnosis , Celiac Disease/immunology , Celiac Disease/urine , Cross-Sectional Studies , Diagnostic Self Evaluation , Enzyme-Linked Immunosorbent Assay , Feces/chemistry , Female , Glutens/chemistry , Glutens/immunology , Glutens/metabolism , Humans , Intestinal Elimination , Male , Middle Aged , Peptides/chemistry , Peptides/immunology , Peptides/metabolism , Point-of-Care Testing , Prospective Studies , Surveys and QuestionnairesABSTRACT
AIMS: Our objectives were to: (1) determine whether celiac disease (CD) patients have cognitive impairment at diagnosis; and (2) compare their cognitive performance with nonceliac subjects who have similar chronic symptoms and healthy controls. MATERIALS AND METHODS: Fifty adults (age range: 18 to 50 y) with symptoms and signs compatible with CD were enrolled in a prospective cohort irrespective of the final diagnosis. At baseline, all individuals underwent cognitive functional and psychological evaluation. CD patients were compared with subjects in whom CD was ruled out and with healthy controls matched by sex, age, and years of schooling. RESULTS: Thirty-three subjects (66%) were diagnosed with CD. Compared with the healthy controls (n=26), CD cases and disease controls (n=17; mostly irritable bowel syndrome) had impaired cognitive performance (P=0.02 and P=0.04, respectively), functional impairment (P<0.01), and higher depression (P<0.01). CD patients had similar cognitive performance and anxiety, but nonsignificant lower depression scores compared with disease controls. CONCLUSIONS: Abnormal cognitive functions detected in newly diagnosed CD adult patients seem not to be disease specific. Our results suggest that cognitive dysfunction could be related to the presence of prolonged symptoms due to a chronic disease.
Subject(s)
Celiac Disease/psychology , Cognitive Dysfunction/epidemiology , Depression/epidemiology , Adolescent , Adult , Case-Control Studies , Chronic Disease , Cohort Studies , Humans , Irritable Bowel Syndrome/psychology , Middle Aged , Prospective Studies , Young AdultSubject(s)
Humans , Breast/pathology , Mammography , Cardiovascular Diseases/diagnosis , Vascular CalcificationSubject(s)
Humans , Male , Atrial Fibrillation/prevention & control , Atrial Fibrillation/epidemiology , Uruguay , Incidence , Prevalence , Risk Factors , Age DistributionABSTRACT
We have recently identified a significant deterioration of bone microarchitecture in premenopausal women with newly diagnosed celiac disease (CD) using high-resolution peripheral quantitative computed tomography (HRpQCT). The aim of this work was to assess changes in bone microarchitecture after 1 year on a gluten-free diet (GFD) in a cohort of premenopausal women. We prospectively enrolled 31 consecutive females at diagnosis of CD; 26 of them were reassessed 1 year after GFD. They all underwent HRpQCT scans of distal radius and tibia, areal BMD by DXA, and biochemical tests (bone-specific parameters and CD serology) at both time points. Secondary, we compared 1-year results with those of a control group of healthy premenopausal women of similar age and BMI in order to assess whether the microarchitectural parameters of treated CD patients had reached the values expected for their age. Compared with baseline, the trabecular compartment in the distal radius and tibia improved significantly (trabecular density, trabecular/bone volume fraction [BV/TV] [p < 0.0001], and trabecular thickness [p = 0.0004]). Trabecular number remained stable in both regions. Cortical density increased only in the tibia (p = 0.0004). Cortical thickness decreased significantly in both sites (radius: p = 0.03; tibia: p = 0.05). DXA increased in all regions (lumbar spine [LS], p = 0.01; femoral neck [FN], p = 0.009; ultradistal [UD] radius, p = 0.001). Most parameters continued to be significantly lower than those of healthy controls. This prospective HRpQCT study showed that most trabecular parameters altered at CD diagnosis improved significantly by specific treatment (GFD) and calcium and vitamin D supplementation. However, there were still significant differences with a control group of women of similar age and BMI. In the prospective follow-up of this group of patients we expect to be able to assess whether bone microarchitecture attains levels expected for their age. © 2016 American Society for Bone and Mineral Research.
Subject(s)
Bone and Bones/pathology , Celiac Disease/diet therapy , Celiac Disease/pathology , Diet, Gluten-Free , Absorptiometry, Photon , Adult , Bone Density , Bone and Bones/diagnostic imaging , Calcium/metabolism , Case-Control Studies , Demography , Dietary Supplements , Female , Humans , Longitudinal Studies , Middle Aged , Patient Compliance , Prospective Studies , Tomography, X-Ray Computed , Vitamin D/therapeutic use , Young AdultABSTRACT
BACKGROUND: We have previously shown a reduction of gastrointestinal symptoms after the oral administration of Bifidobacterium infantis Natren Life Start super strain (NLS-SS) in untreated celiac disease (CD) patients. The symptomatic improvement was not associated with changes in intestinal permeability or serum levels of cytokines, chemokines, or growth factors. Therefore, we hypothesized that the beneficial symptomatic effect observed previously in patients with CD treated with B. infantis may be related to the modulation of innate immunity. GOALS: To investigate the potential mechanisms of a probiotic B. infantis Natren Life Start super strain on the mucosal expression of innate immune markers in adult patients with active untreated CD compared with those treated with B. infantis×6 weeks and after 1 year of gluten-free diet (GFD). METHODS: Numbers of macrophages and Paneth cells and α-defensin-5 expression were assessed by immunohistochemistry in duodenal biopsies. RESULTS: We showed that GFD decreases duodenal macrophage counts in CD patients more effectively than B. infantis. In contrast, B. infantis decreases Paneth cell counts and expression of α-defensin-5 in CD (P<0.001). CONCLUSIONS: The results identify differential innate immune effects of treatment with B. infantis compared with 1 year of GFD. Further studies are needed to investigate synergistic effects of GFD and B. infantis supplementation in CD.
Subject(s)
Bifidobacterium longum subspecies infantis/growth & development , Celiac Disease/therapy , Diet, Gluten-Free , Duodenum/metabolism , Immunity, Innate , Immunity, Mucosal , Intestinal Mucosa/metabolism , Probiotics/therapeutic use , alpha-Defensins/metabolism , Adult , Biomarkers/metabolism , Biopsy , Celiac Disease/immunology , Celiac Disease/metabolism , Celiac Disease/microbiology , Down-Regulation , Duodenum/immunology , Duodenum/microbiology , Female , Gastrointestinal Microbiome , Humans , Immunohistochemistry , Intestinal Mucosa/immunology , Intestinal Mucosa/microbiology , Macrophages/immunology , Macrophages/metabolism , Macrophages/microbiology , Male , Middle Aged , Paneth Cells/immunology , Paneth Cells/metabolism , Paneth Cells/microbiology , Probiotics/adverse effects , Time Factors , Treatment Outcome , Young AdultABSTRACT
Background/Aim. Reflux symptoms (RS) are common in patients with celiac disease (CD), a chronic enteropathy that affects primarily the small intestine. We evaluated mucosal integrity and motility of the lower esophagus as mechanisms contributing to RS generation in patients with CD. Methods. We enrolled newly diagnosed CD patients with and without RS, nonceliac patients with classical reflux disease (GERD), and controls (without RS). Endoscopic biopsies from the distal esophagus were assessed for dilated intercellular space (DIS) by light microscopy and electron microscopy. Tight junction (TJ) mRNA proteins expression for zonula occludens-1 (ZO-1) and claudin-2 and claudin-3 (CLDN-2; CLDN-3) was determined using qRT-PCR. Results. DIS scores were higher in patients with active CD than in controls, but similar to GERD patients. The altered DIS was found even in CD patients without RS and normalized after one year of a gluten-free diet. CD patients with and without RS had lower expression of ZO-1 than controls. The expression of CLDN-2 and CLDN-3 was similar in CD and GERD patients. Conclusions. Our study shows that patients with active CD have altered esophageal mucosal integrity, independently of the presence of RS. The altered expression of ZO-1 may underlie loss of TJ integrity in the esophageal mucosa and may contribute to RS generation.
Subject(s)
Celiac Disease/complications , Celiac Disease/pathology , Esophagus/pathology , Gastroesophageal Reflux/complications , Mucous Membrane/pathology , Tight Junctions/pathology , Adolescent , Adult , Aged , Biopsy , Celiac Disease/diet therapy , Claudin-3/genetics , Claudins/genetics , Esophageal pH Monitoring , Esophagus/physiopathology , Extracellular Space , Female , GTP-Binding Proteins/metabolism , Gene Expression , Humans , Male , Manometry , Middle Aged , Mucous Membrane/metabolism , Protein Glutamine gamma Glutamyltransferase 2 , RNA, Messenger/metabolism , Tight Junctions/metabolism , Transglutaminases/metabolism , Young Adult , Zonula Occludens-1 Protein/geneticsABSTRACT
RESUMEN: Objetivo: Valorar la frecuencia y severidad de la cardiotoxicidad inducida por Trastuzumab (TTZ) en pacientes portadoras de cáncer de mama (CM) HER 2 positivo, asistidas en los Servicios de Oncología del Hospital de Clínicas y de la Asociación Española Primera en Salud. Métodos: Estudio observacional retrospectivo, que incluyó pacientes del Hospital de Clínicas y de la Asociación Española diagnosticadas de CM HER 2 positivo, que recibieron tratamiento con TTZ entre enero de 2007 y diciembre de 2013. Resultados: Se incluyeron 69 pacientes, la mayoría de las cuales tuvieron CM localizado, y cuya media de edad fue 50,1 años. 27% de las pacientes presentó cardiotoxicidad, y el 26% de éstas desarrolló insuficiencia cardíaca sintomática; todas recibieron tratamiento médico adecuado, siendo la insuficiencia cardíaca reversible en la mayoría de los casos. Conclusiones: La frecuencia de cardiotoxicidad observada en el estudio fue del 27 % (IC 95 %: 16,27; 38,8). Con las limitaciones propias del estudio, éste permite verificar similitudes con otras poblaciones reportadas, variando la frecuencia entre 3,7 y 34 %. Sin embargo, la proporción de pacientes que presentaron insuficiencia cardíaca sintomática (7%) fue algo superior a la reportada en la literatura, que es del 4%. La cardiotoxicidad fue reversible en la mayoría de las pacientes.
ABSTRACT: Objective: To evaluate the frequency and severity of Trastuzumab-induced cardiotoxicity in HER2 positive breast cancer (BC) patients assisted in Oncologic Services of the Hospital de Clínicas and Asociación Española Primera en Salud. Methods: Retrospective observational study of HER2 positive BC patients from Hospital de Clínicas and Asociación Española under systemic therapy with Trastuzumab (TTZ) from January 2007 to December 2013. Results: The study included 69 patients, most were early BC, mean age was 50,1 years . 27% of the patients developed cardiotoxicity and 26 % of them developed symptomatic heart failure. All patients received adequate medical treatment and the most instances were reversible Conclusions: The frequency of cardiotoxicity observed in the study was 27% (IC 95 %: 16,27; 38,8). With the limitations of the study, it can verify reported similarities with other populations, oscillating frequency between 3.7 and 34%. However, the proportion of patients who had symptomatic heart failure (7%) was higher than that reported in the literatura wich is 4%. Cardiotoxicity was reversible in most patients.
Subject(s)
Celiac Disease/diagnosis , GTP-Binding Proteins/immunology , Gliadin/immunology , Immunoglobulin A/immunology , Immunoglobulin G/immunology , Practice Guidelines as Topic , Transglutaminases/immunology , Adult , Celiac Disease/genetics , Celiac Disease/immunology , Cohort Studies , HLA-DQ Antigens/genetics , Humans , Prospective Studies , Protein Glutamine gamma Glutamyltransferase 2 , Sensitivity and SpecificityABSTRACT
BACKGROUND: Celiac disease (CD) is mostly recognized among subjects with a Caucasian ethnic ancestry. No studies have explored conditions predisposing Amerindians to CD. OBJECTIVE: To prospectively assess environmental, genetic and serological conditions associated with CD among members of the Toba native population attending a multidisciplinary sanitary mission. METHODS: An expert nutritionist determined daily gluten intake using an established questionnaire. Gene typing for the human leukocyte antigen (HLA) class II alleles was performed on DNA extracted from peripheral blood (HLA DQ2/DQ8 haplotype). Serum antibodies were immunoglobulin (Ig) A tissue transglutaminase (tTG) and the composite deamidated gliadin peptides/tTG Screen test. Positive cases were tested for IgA endomysial antibodies. RESULTS: A total of 144 subjects (55% female) were screened. The estimated mean gluten consumption was 43 g/day (range 3 g/day to 185 g/day). Genetic typing showed that 73 of 144 (50.7%) subjects had alleles associated with CD; 69 (94.5%) of these subjects had alleles for HLA DQ8 and four had DQ2 (5.5%). Four and six subjects had antibody concentrations above the cut-off established by the authors' laboratory (>3 times the upper limit of normal) for IgA tTG and deamidated gliadin peptides/tTG screen, respectively. Four of these had concomitant positivity for both assays and endomysial antibodies were positive in three subjects who also presented a predisposing haplotype. CONCLUSION: The present study was the first to detect CD in Amerindians. The native Toba ethnic population has very high daily gluten consumption and a predisposing genetic background. We detected subjects with persistent CD autoimmunity and, at least, three of them fulfilled serological criteria for CD diagnosis.
Subject(s)
Celiac Disease/ethnology , Diet/statistics & numerical data , Glutens , Indians, South American/statistics & numerical data , Adolescent , Adult , Aged , Argentina/epidemiology , Autoantibodies/immunology , Autoimmunity/genetics , Autoimmunity/immunology , Celiac Disease/genetics , Celiac Disease/immunology , Child , Child, Preschool , Female , GTP-Binding Proteins/immunology , Gliadin/immunology , HLA-DQ Antigens/genetics , Humans , Immunoglobulin A/immunology , Male , Middle Aged , Prevalence , Prospective Studies , Protein Glutamine gamma Glutamyltransferase 2 , Transglutaminases/immunology , Young AdultABSTRACT
BACKGROUND: Obesity is associated with systemic co-morbi- dities. Conservative management has a low rate ofsuccess in the short and long term. Therefore, novel endoscopic strate- gies have emerged as alternative therapies to bariatric sur- gery. The intragastric balloon (IGB) is a temporary, effective and safe endoscopic treatment for weight loss. Objectives. 1. To describe changes in body mass index (BMI) in patients who completed treatment with IGB. 2. To describe metabo- lic co-morbidities and psychological features at admission. MATERIAL AND METHODS: Patients with an age equal to or higher than 13 years-old were evaluated by a multidiscipli- nary team and categorized as "suitable" for IGB. The study took place in aprivate center in Buenos Aires, Argentina, bet- ween November 2007 andNovember 2012. The design was interventionist, longitudinal, comparative and retrospective. Interventions were: a) IGB placement was done with the usual technique; b) Nutritional monitoring was performed and a low calorie diet and an exercise plan were indicated. Follow-up was performed monthly. Main outcome measu- rements were: 1) Changes in BMI between baseline and at IGB removal according to diet and exercise compliance, 2) metabolic co-morbidities, 3) psychological traits evaluated wit checklist SCL 90. RESULTS: We included 385 patients, 66% female, mean age 41 years (range 13 to 70 years). A BMI decrease of 5 points (13 kg) was observed in the overall sample and in the 322 patients (83.6%) who completed 6 months (14 kg) (NS). The weight loss was greater in those who were compliant to diet and exercise (P = 0.0001). Most prevalent metabolic co-morbidities and psychological traits were dyslipemia and depression, respectively. CONCLUSIONS: IGB was effective in all patients. Weight loss was greater in patients compliant to diet and exercise.
